Literature DB >> 6897686

Nephritic factor (NeF) of alternate pathway (NeFA) and of classical pathway (NeFc).

M Arakawa, J Seino, Y Kinoshita, K Fukuda, T Saito, T Furuyama.   

Abstract

NeFA and NeFc were studied in various cases (115 cases). 5 cases were followed up for a long time. NeFA assay was done by the "microtest plate method". We detected the NeF activity for the first time in the cases of Sjögren syndrome (SjS) and SjS+SLE+Hashimoto's disease (Hashimoto). In some cases NeF activity disappeared after therapy, and in one case NeFA and NeFc were positive at first, but then only NeFA activity became negative following the adequate therapy. As to the antibody nature of NeF, the possibility was suggested that NeFA might be anti C3b autoantibody and NeFc might be anti C4b and/or C4b2a auto-antibody.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6897686     DOI: 10.1620/tjem.138.401

Source DB:  PubMed          Journal:  Tohoku J Exp Med        ISSN: 0040-8727            Impact factor:   1.848


  2 in total

1.  Different Aspects of Classical Pathway Overactivation in Patients With C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis.

Authors:  Marloes A H M Michels; Nicole C A J van de Kar; Sanne A W van Kraaij; Sebastian A Sarlea; Valentina Gracchi; Flore A P T Engels; Eiske M Dorresteijn; Johannes van der Deure; Caroline Duineveld; Jack F M Wetzels; Lambertus P W J van den Heuvel; Elena B Volokhina
Journal:  Front Immunol       Date:  2021-08-11       Impact factor: 7.561

2.  Heterogeneity, polypeptide chain composition and antigenic reactivity of autoantibodies (F-42) that are directed against the classical pathway C3 convertase of complement and isolated from sera of patients with systemic lupus erythematosus.

Authors:  M R Daha; H M Hazevoet; L A van Es
Journal:  Clin Exp Immunol       Date:  1984-06       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.